Our mission

Decode functional gene networks for safer, more effective therapies for patients

Algen
Who we are

We are a team of trailblazing scientists, data engineers and drug developers finding drugs that alter the course of tough-to-treat diseases with minimal toxicity

Biology

Biology

  • RNA biology & RNA-guided mechanisms of gene regulation
  • Innovative CRISPR applications
  • Single cell functional genomics
AI

Artificial Intelligence

  • Deep learning to decode gene signaling networks & quantify wide-scale single cell gene modulation
  • Human-centric, multi-omics data generation and analytics throughout disease progression
  • Novel applications across multiple disease verticals
Drug Development

Drug Development

  • Target ID & validation based on translatable therapeutic metrics
  • Drug development from target to clinic
  • Novel preclinical models

Meet The Team

Leadership
Chun-Hao Huang, PhD
Chun-Hao Huang, PhD
CEO & Co-Founder
Christine Du, MBA
Christine Du, MBA
CBO & Co-Founder
Jeff Whitten, PhD
Jeff Whitten, PhD
CSO
Advisors
Jennifer Doudna, PhD
Jennifer Doudna, PhD
Frank McCormick, PhD
Frank McCormick, PhD
Matthew Rabinowitz, PhD
Matthew Rabinowitz, PhD
Cole Trapnell, PhD
Cole Trapnell, PhD
Spencer Knight, PhD
Spencer Knight, PhD

Our Investors

Our success is driven not only by our innovation but also by the strategic partnerships we've forged with some of the world's most accomplished investors

Publications

Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
View publication
Arrow
Trends in Cancer - Cell Press
A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets
p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression

Work with us

We are on a groundbreaking journey to redefine possibilities in biology

AlgenBio Jobs

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.